We’re revolutionizing
the treatment of cancer and auto-immune disorders

We’re revolutionizing
the treatment of cancer
and auto-immune disorders


A paradigm shift in
hematological cancer and
auto-immunity treatment

Millions of people suffer from life threatening auto-immune disorders in developed countries alone, with another half million languishing from hematological cancers. The current treatment landscape for these conditions relies on broad-spectrum proteasome inhibitors that indiscriminately impact both constitutive and immunoproteasomes, limiting therapeutic progress beyond multiple myeloma (MM) and mantle cell lymphoma (MCL). It also produces severe side effects that are so awful that many patients prefer to forego treatment entirely rather than deal with the extreme discomfort, heart and nerve disorders that accompany it.

Enter iProtics, with its next-generation approach to treatment. Rather than indiscriminately targeting all cells (constitutive proteasome), as is the current practice, iProtics intelligently zeroes in on only  immunoproteasome in malignant cells. Such targeted treatment eliminates adverse side effects, while simultaneously increasing the treatment’s effectiveness, making it a viable new drug for auto-immunity treatment.

The Technology

Healthy treatment, healthy returns

The unique properties of our peptide-based inhibitors set them apart from existing clinical and academic  proteasome inhibitors. Our innovation is achieved by merging three compounds that individually target the proteasome subunits β1i, β2i, and β5i into a single, compact molecule: iProtics’ lead asset, IP071. While resembling the design of the clinical proteasome inhibitor
Carfilzomib, IP071 outperforms it and other existing inhibitors (with a 12-fold selectivity window), without inducing toxic side effects. With current clinical inhibitors indiscriminately affecting both immunoproteasomes and constitutive proteasomes, this breakthrough offers an exciting paradigm shift in drug development.

The Background

Twenty years of
proteasome inhibitor
Twenty years of
proteasome inhibitor

Elmer Maurits, CEO

Building upon the remarkable discoveries made by the renowned Overkleeft Group at Leiden University, iProtics is currently in the middle of pre-clinical trials. Under the leadership of CEO Dr. ir. Elmer Maurits, the iProtics team is poised to make significant contributions to a rapidly growing area of medicine. With eight years of experience in chemical development, including work with Kezar Life Sciences, Dr. Maurits has assembled an enviable team of experts in drug development, business strategy and bioorganic chemistry. Patrick Dekker Msc., the Chief Scientific Officer, oversees pre-clinical development, while Prof. dr. Herman S. Overkleeft and Dr. Bogdan I. Florea serve as Scientific Advisors and contribute specialized knowledge. Dr. Wil Hazenberg and Dr. Math Kohnen, both Business Developers, bring valuable experience in venture capital and strategic planning. The iProtics team’s comprehensive approach, combining scientific expertise with business acumen, has been key in enabling them to successfully transition from academia to pre-clinical trials.

The Mission

Meeting human need
with human ingenuity

While many talk about improving the quality of life, iProtics is dedicated to it. By moving the industry beyond the use of indiscriminate drugs into the application of smart drugs that target only disease-causing cells, iProtics preserves the integrity of healthy tissues even as it preserves the dignity and well-being of patients. iProtics plans on establishing itself firmly as a major player in the treatment of hematological cancers and auto-immune disorders.

Get in touch

Please use this form to ask us anything, share an insight, or express interest in collaboration or investment.

We’ll get back to you ASAP.

In the meantime, why not follow us on LinkedIn?